SCHEMBL3424668

SCHEMBL3424668

COc1ccc(C(=O)O)c2c1CCCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
RXRA P19793 3/20 0.47
RXRB P28702 2/20 0.47
RXRG P48443 2/20 0.47
ALDH1A1 P00352 3/20 0.46
CDC25B P30305 1/20 0.44
ADRA1A P35348 1/20 0.44
FABP4 P15090 1/20 0.42
KDM4E B2RXH2 2/20 0.42
HPGD P15428 2/20 0.42
HTT P42858 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA7 P43166 1/20 0.42
TPMT P51580 1/20 0.42
CA9 Q16790 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427457 0.86 ALDH1A1 (0.50) MAPTTDP1ALDH1A1ADRA1AKDM4E
SCHEMBL9576976 0.83 HMGCR (0.47) MAPTTDP1RXRARXRBRXRG
SCHEMBL8295144 0.83 ADRA1A (0.45) TDP1ALDH1A1ADRA1AKDM4EHPGD
SCHEMBL87519 0.82 CYP1A2 (0.57) MAPTTDP1RXRARXRBRXRG
SCHEMBL12918718 0.82 HTT (0.52) MAPTRXRARXRBRXRGALDH1A1
SCHEMBL12565602 0.82 ALDH1A1 (0.50) MAPTTDP1ALDH1A1ADRA1AKDM4E
SCHEMBL250454 0.80 CYP1A2 (0.55) MAPTTDP1RXRARXRBRXRG
SCHEMBL3091854 0.80 CYP1A2 (0.55) MAPTTDP1RXRARXRBRXRG
SCHEMBL2034342 0.80 CYP1A2 (0.55) MAPTTDP1RXRARXRBRXRG
SCHEMBL195800 0.80 CYP1A2 (0.55) MAPTTDP1RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662750-B2 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2010-02-16 US disclosed
US-7662750-B2 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2010-02-16 US disclosed
US-7662750-B2 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2010-02-16 US disclosed
US-20050153366-A1 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2005-07-14 US disclosed
WO-2005057171-A2 PROTEIN-PROTEIN INTERACTION ANTAGONIST SCREENING LIBRARIES BASED UPON 1,4-DISUBSTITUTED NAPHTHALENES AND RELATED SCAFFOLDS THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153366-A1 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds RIPK4, RIPK2, ATRIP MAPT 3459/4885TDP1 3151/4885RXRA 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.